PHS
ARQT icon

PFM Health Sciences’s Arcutis Biotherapeutics ARQT Stock Holding History

PFM Health Sciences’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.35M Buy
+242,069
New +$5.64M 0.54% 58
2025
Q4 		– Sell
-360,460
Closed -$6.79M – 80
2025
Q3 		$6.79M Sell
360,460
-562,915
-61% -$8.88M 0.52% 46
2025
Q2 		$12.9M Buy
+923,375
New +$12.9M 1.1% 30

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PFM Health Sciences's ARQT Position: Q2 2026 in Review

PFM Health Sciences opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 242,069 shares worth $6.35M. The stake represents 0.54% of the portfolio and ranks #58 among its holdings. This is a return to the name: PFM Health Sciences previously reported a position in ARQT as recently as Q3 2025.

PFM Health Sciences first reported a position in ARQT in Q2 2025 and has held it in 3 quarters since. The position peaked at $12.9M in Q2 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • PFM Health Sciences held 242,069 shares of Arcutis Biotherapeutics worth $6.35M as of Q2 2026.
  • Arcutis Biotherapeutics was a new PFM Health Sciences position in Q2 2026.
  • Arcutis Biotherapeutics made up 0.54% of PFM Health Sciences's portfolio in Q2 2026, its #58 holding.
  • PFM Health Sciences first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 3 quarters since.
  • PFM Health Sciences's Arcutis Biotherapeutics position peaked at $12.9M in Q2 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.